Kostas Manolis
Partner and Head of Unquoted Investments @ Downing Ventures
London, United Kingdom
Kostas Manolis is a post-ipo equity investor at Downing Ventures in London focused on Health Care and Biotechnology. Kostas joined Downing as a Partner in 2015. He works across the Investment team and is a member of the Downing Ventures Investment Committee. He has more than 13 years’ private equity experience as investor, board director, portfolio manager, adviser and business angel. Kostas worked as a corporate finance advisor at PwC, where he advisedinstitutions and management teams on private equity deals and later joined the private equity team of Bank of Scotland in 2006. He was a member of the Caird Capital team that led a successful spin out of a £0.5 billion private equity portfolio from Lloyds Banking Group in 2010. Kostas has worked with management teams through operational improvement, growth, turnaround and successful exits. Kostas holds a degree in Biochemistry and a PhD in Molecular Genetics and is a Chartered Accountant with ICAEW.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Kostas Manolis invests in
Stages Kostas Manolis invests in
Countries Kostas Manolis invests in
Investment Focus
Industry
- Health Care 1 (50%)
- Biotechnology 1 (50%)
- Pharmaceutical 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Destiny Pharma
|
Destiny Pharma is an innovative pharmaceutical company dedicated to the development of novel antimicrobial products.Our XF series of compounds have a mechanism of action that is fundamentally different from all existing antibiotics. As the likelihood of resistance developing is very remote, they offer potential advantages in controlling thedrug-resistant bacteria that are at the centre of a global healthcare crisis. | $24M / Post-IPO Equity / Dec 04, 2017 | |
|
Destiny Pharma
|
Destiny Pharma is an innovative pharmaceutical company dedicated to the development of novel antimicrobial products.Our XF series of compounds have a mechanism of action that is fundamentally different from all existing antibiotics. As the likelihood of resistance developing is very remote, they offer potential advantages in controlling thedrug-resistant bacteria that are at the centre of a global healthcare crisis. | $20M / Post-IPO Equity / Oct 04, 2017 |
About Downing Ventures
Downing Ventures is a division of Downing LLP. They invest venture capital into early and growth stage technology businesses. Our belief is that technology now forms an integral part of the everyday lives of consumers, corporations and governments. Further, they believe that they are now experiencing the benefits of the second wave of technologydevelopment, which is now based on sound infrastructure. Investing into this trend, they look for: Visionary entrepreneurs, with the ability to execute as well as dream. Large (potential) addressable markets. Distinct product / service advantages. Limited adoption risk for customers. They seek to invest 250,000 to 5 million per company. They will invest in seed-stage deals and Series A deals, and then look to continue to support those companies through phases of subsequent growth. Fundamentally, they back entrepreneurs. They are supportive, hopefully helpful, investors.
Downing Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Kostas Manolis
Partner and Head of Unquoted Investments
|
|||
Mike Kennedy
Ventures Adviser - Downing Ventures
|
|||
Nick Lewis
Founding Partner, Investment Committee Member & Chairman
|
|||
Sophie Andre
Portfolio and Operations Manager
|
|||
Chris Allner
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Kostas Manolis invest in?
Kostas Manolis invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Post-IPO Equity stage. Most of the 2 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Kostas Manolis last invest?
The most recent investment recorded for Kostas Manolis closed in Dec 2017. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
